Navigation Links
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Date:5/31/2008

- Poster Presented at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, May 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC). Results demonstrated that picoplatin can be safely administered with full doses of docetaxel. In addition, the prostate specific antigen (PSA) response rate was 69 percent in 26 patients evaluable for PSA.

The Company presented the Phase 2 data (abstract #5153) in the General Poster Session during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations.

"The promising results of this Phase 2 trial in HRPC support further development of picoplatin in the treatment of prostate cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "A prospective randomized trial is under consideration. The combination of picoplatin with a taxane could be further evaluated in other tumor types, such as ovarian cancer and non-small cell lung cancer."

Phase 2 HRPC Study Preliminary Results

In the ongoing Phase 2 trial, the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every 21 days in combination with full-dose docetaxel (75 mg/m squared) with dail
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Ga., June 21, 2011 Molnlycke Health Care U.S., ...  James G. Wetrich has been appointed to the position ... will lead both the Surgical and Wound Care Divisions ... has been appointed to the position of President, U.S. ...
... A new study published in the June edition of ... uniform distribution of endovascular coils may help in the ... & Shurtleff, Inc. (Codman), a global neurovascular and neuroscience ... study. Study authors found that the ...
Cached Medicine Technology:Molnlycke Health Care U.S. Announces Senior Management Changes 2New Study Explores Impact of More Uniform Distribution of Endovascular Coils in Cerebral Aneurysm Treatment 2New Study Explores Impact of More Uniform Distribution of Endovascular Coils in Cerebral Aneurysm Treatment 3
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... announces that the Journal of the American Society of ... in MEDLINE. MEDLINE is the premier bibliographic database of the ... journal article citations, with a concentration on biomedicine. "The ... JASH has been added to the MEDLINE journal collection," ...
... will discuss the impact of health information technology on ... symposium at 1 p.m. PT Friday, Oct. 1, as ... American Academy of Pediatrics (AAP) in San Francisco. ... Health Information Technology (HIT) in the U.S. Department of ...
... the Journal of Thoracic Oncology (JTO), data ... the safety and efficacy profile of erlotinib, a highly ... receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous ... has been shown to significantly increase survival for patients ...
... by University of California, San Diego researchers 14 years earlier, ... with just enough sleep. Less than five hours a night ... A team of scientists, headed by Daniel F. Kripke, ... of Medicine, revisited original research conducted between 1995 and 1999. ...
... Mass. -- MIT researchers and collaborators from Tufts University have ... a critical compound that is a precursor to the cancer ... yew tree. The tree,s bacteria can produce 1,000 times more ... microbial strain. The technique, described in the Oct. 1 ...
... By Kathleen Doheny HealthDay Reporter , THURSDAY, ... infertility often escapes experts, but scientists have found a ... "This may be the most frequent single gene ... date, with 4 percent of men with unexplained severe ...
Cached Medicine News:Health News:JASH accepted for coverage in MEDLINE 2Health News:TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer 2Health News:Women's study finds longevity means getting just enough sleep 2Health News:Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol 2Health News:Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol 3Health News:Genetic Glitch Tied to Disrupted Sperm Production 2
... Easy-On Knee Brace features an adjustable ... 0to 135 in 10 increments. Adjust ... to expose the stop pins and ... thick, self-padded washable fabric with Velcro ...
... Aircast Patellar Brace is a support designed ... shaped aircell stabilizes the patella and compresses ... position of the patella. During ambulation, the ... reduce swelling and pain. A moveable aircell ...
... the therapeutic benefits of controlled compression to minimize ... The cuff is anatomically designed to completely fit ... is available in three sizes for adults and ... for children 1 - 7 years of age. ...
Unique supportive clavicle splint. Features front closure design for convenience in application. Comfortable padding over clavicle area....
Medicine Products: